Clinical trials: Viral Pneumonia
COVID-19
A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)
This study will determine the immunogenicity of Spikogen in vaccine naïve individuals. Spikogen will be administered as two doses 1 month apart with a third booster dose either 1 or 3 months after the second dose.
- Trial name
- NCT05279456
- Testing
- Advax-CpG55.2 adjuvanted recombinant spike protein
- Where
- Australia
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Coronavirus Infections, Severe Acute Respiratory Syndrome
Household Transmission Investigation Study for COVID-19 in Tropical Regions
This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed…
- Conditions
- Coronavirus Infections, Severe Acute Respiratory Syndrome, SARS-CoV Infection
- Trial name
- EPI-COVID-19 (NCT04328129)
- Testing
- Human biological samples
- Where
- 4 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults
SCTV01C-02-1 is a randomized, double-blind, placebo controlled Phase Ⅰ/Ⅱ clinical trial of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant bivalent trimeric S protein vaccine manufactured by…
- Trial name
- NCT05148091
- Testing
- SCTV01C, Adjuvant, Saline
- Where
- 5 sites in China
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19, Coronavirus
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning
The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.
- Conditions
- COVID-19, Coronavirus, Mortality
- Trial name
- IDENTIFY (NCT04423991)
- Testing
- COViage
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Dascena
Covid19
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19
This is a randomized, placebo-controlled study to assess the safety, PK profile, and efficacy of COVI-AMG in subjects with COVID-19.
- Trial name
- NCT04584697
- Testing
- COVI-AMG
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
A Bridging Study of FB2001 in Healthy Subjects
In the first human clinical trial conducted in the United States, single and multiple dosing of FB2001 in multiple dose groups were partially completed，and FB2001 demonstrated good safety and tolerability.
- Trial name
- NCT05197179
- Testing
- FB2001
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Frontier Biotechnologies Inc.
Covid19
Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)
This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are either asymptomatic or have…
- Trial name
- NCT04906694
- Testing
- COVI-DROPS
- Where
- 18 sites in United States
- Volunteers
- 97 people
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years
This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine (CoronaVac)manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05112913
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2
- Where
- China
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
SARS-CoV-2 Infection, Influenza A
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
This will be a prospective study for the clinical validation of the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test for the qualitative detection and differentiation of SARS-CoV-2, Influenza A, Influenza B and RSV in AN…
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B, RSV
- Trial name
- CorDx 4in1 (NCT07875270)
- Testing
- Flu A/B/COVID-19 + RSV Multiplex Rapid Test
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- CorDx, Inc.
Coronavirus Disease 2019 (COVID-19)
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, a Combination…
- Trial name
- ENDURE (NCT05375760)
- Testing
- AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
- Where
- 16 sites in United States
- Volunteers
- 251 people
- Sponsor
- AstraZeneca
Covid19
Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test
Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.
- Trial name
- ASPIRE (NCT04557046)
- Testing
- Nasal Swab, Nasopharyngeal swab, Throat swab
- Where
- 7 sites in United States
- Volunteers
- 1,134 people
- Sponsor
- LumiraDx UK Limited
Covid19
COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
This is a phase 1/2 study in adult healthy subjects that have previously been vaccinated with an FDA-authorized vaccine against COVID-19.
- Trial name
- NCT04845191
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Coronavirus Disease 2019 (COVID-19)
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in…
- Trial name
- PREVENT-HD (NCT04508023)
- Testing
- Rivaroxaban, Standard of Care (SOC)
- Where
- 17 sites in United States
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
COVID
Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
GC004 is a Phase I trial to evaluate the safety and the immune responses of a therapeutic vaccine in SARS-CoV-2 infected patients.
- Trial name
- NCT04428073
- Testing
- Covax-19™
- Volunteers
- 32 people
- Sponsor
- GeneCure Biotechnologies
COVID-19
A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers
This is a prospective, epidemiological, cohort study to assess the feasibility of screening healthy asymptomatic workers for the presence of severe acute respiratory syndrome SARS-CoV-2 by pharyngeal swaps and serology at…
- Trial name
- NCT04405466
- Testing
- Blood sampling, Throat swab
- Where
- Germany
- Volunteers
- 417 people, healthy volunteers welcome
- Sponsor
- Miltenyi Biomedicine GmbH
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
COVID-19
Desidustat in the Management of COVID-19 Patients
This study is a Phase 2b, Multicenter, Open-label, Randomized, Comparator- Controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of mild, moderate and severe COVID-19 patients.
- Trial name
- NCT04463602
- Testing
- Desidustat, Standard of Care
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited
Post COVID-19 Condition
Post-COVID-19 Patients With Trak Tool
The clinical trial aims to analyse the effectiveness of a physiotherapeutic exercise program delivered through the telerehabilitation tool (Trak) compared to a booklet-based rehabilitation format in post-COVID-19 patients.
- Trial name
- TRAK-COVID (NCT06492551)
- Testing
- Trak exercise prescription protocol, Conventional rehabilitation plan in the gym
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Trak Health Solutions S.L.
COVID-19
Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation
This is a one-site, interventional, prospective, single-arm, open-label, controlled phase-IIa trial evaluating the safety and efficacy of palbociclib in hospitalized, moderate COVID- 19 cases.
- Trial name
- CDK6COV (NCT05371275)
- Testing
- Palbociclib
- Where
- Germany
- Sponsor
- biotx.ai GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.